Florian Solzbacher

person active confidence: Medium status: Draft updated 2026-06-19

Type
person
Status
Draft
Confidence
Medium
Tier
B
Builder-tier
S
Activity-signal
2026-02-20 · https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2026.1714738/full
Activity-checked
2026-08-14
Focus
neuroengineering, brain-computer interfaces, medical devices, university spinouts
Primary Location
Salt Lake City, UT
Utah Location
Salt Lake City, UT
Region
Salt Lake City
Updated
2026-06-19

Summary

Florian Solzbacher co-founded Blackrock Neurotech to commercialize the Utah Electrode Array when brain-computer interfaces barely existed as a market. Sustaining that platform helped make high-channel human neural recording available worldwide, structurally advancing an entire research sector.

Impact

Solzbacher turned a decades-long University of Utah neuroengineering research program into a commercial BCI company at a time when the BCI sector barely existed commercially. The Utah Array became the foundational research tool for a generation of BCI scientists globally, which means Blackrock's commercial success is downstream of an ecosystem effect Solzbacher helped sustain. His presence in the Salt Lake City neuroengineering cluster — alongside the SCI Institute, Ripple Neuro, and Iris Biomedical — makes him a connective node for talent and research in that domain.

What They Offer

Deep experience commercializing neural-interface hardware from a university research base; understanding of FDA IDE and PMA pathways for active implantable devices; network connections across the global BCI research community and the Utah neuroengineering cluster specifically.

What They're Looking For

Not known from public sources. Inference: most likely engaged with neuroengineering, hard-technology medical devices, and university spinout questions in the neural-interface space.

Track Record

  • Co-founded Blackrock Neurotech (2008), commercializing the Utah Electrode Array
  • Led Blackrock through two decades of clinical research tool deployment across 30,000+ implantation days
  • Navigated Tether Evo's $200M majority stake acquisition (April 2024)

Good Fits

BCI founders or medical-device engineers building implantable neurotechnology; researchers moving from academic neuroengineering into commercial products; founders navigating FDA active-implant pathways.

Public Connection Path

Blackrock Neurotech and University of Utah neuroengineering channels.

Evidence

See Also

Open Questions

  • What is Solzbacher's current operational role after the Tether Evo majority stake acquisition?
  • Is he still active at the University of Utah in an advisory or research capacity?